Dr. Steven Attia, DO
What this data tells you about Dr. Attia
Dr. Steven Attia is a hematology & oncology in Jacksonville, FL, with 19 years in practice. Based on federal Medicare data, Dr. Attia performed 128,841 Medicare services across 2,903 unique beneficiaries.
Between the years covered by Open Payments, Dr. Attia received a total of $1,370 from 3 pharmaceutical and/or device companies across 3 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Attia is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Nivestym) for white blood cells | 18,600 | $0 | $1 |
| Pembrolizumab injection (Keytruda) | 13,602 | $36 | $175 |
| Darbepoetin injection (Aranesp) for anemia | 11,985 | $2 | $11 |
| Anti-nausea injection (fosaprepitant) | 11,400 | $0 | $1 |
| Iron infusion (Feraheme) | 11,220 | $0 | $2 |
| Nivolumab injection (Opdivo) | 9,640 | $22 | $108 |
| Oxaliplatin chemotherapy injection | 8,800 | $0 | $1 |
| Daratumumab injection (Darzalex) | 7,920 | $38 | $190 |
| Injection, paclitaxel protein-bound particles, 1 mg | 5,056 | $10 | $51 |
| Paclitaxel chemotherapy injection | 4,212 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 4,020 | $19 | $89 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 3,170 | $23 | $183 |
| Dexamethasone injection (steroid) | 2,982 | $0 | $4 |
| Injection, carfilzomib, 1 mg | 2,430 | $36 | $174 |
| Anti-nausea injection (ondansetron/Zofran) | 2,008 | $0 | $5 |
| Immune globulin infusion (Gammagard) | 1,980 | $36 | $137 |
| Injection, bortezomib, 0.1 mg | 1,285 | $4 | $9 |
| Injection, atropine sulfate, 0.01 mg | 1,000 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,000 | $22 | $192 |
| Anti-nausea injection (Aloxi/palonosetron) | 730 | $1 | $9 |
| Injection of additional new drug or substance into vein | 702 | $12 | $216 |
| Administration of chemotherapy into vein, 1 hour or less | 417 | $100 | $869 |
| Injection, fluorouracil, 500 mg | 413 | $2 | $28 |
| Injection, irinotecan, 20 mg | 400 | $2 | $25 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 360 | $3 | $35 |
| Injection, leucovorin calcium, per 50 mg | 222 | $3 | $24 |
| Office visit, established patient (30-39 min) | 197 | $94 | $450 |
| Collection of blood sample from implanted device | 186 | $20 | $135 |
| Drug injection, under skin or into muscle | 185 | $11 | $102 |
| Injection, carboplatin, 50 mg | 183 | $2 | $31 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 183 | $137 | $498 |
| Infusion, normal saline solution , 1000 cc | 182 | $2 | $82 |
| Office visit, established patient (20-29 min) | 169 | $62 | $296 |
| Infusion into a vein for hydration, each additional hour | 168 | $10 | $114 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 168 | $78 | $473 |
| Cyclophosphamide, 100 mg | 145 | $16 | $117 |
| Injection, magnesium sulfate, per 500 mg | 144 | $1 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 134 | $50 | $446 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 133 | $22 | $233 |
| Administration of chemotherapy into vein, each additional hour | 132 | $22 | $212 |
| Injection, potassium chloride, per 2 meq | 115 | $0 | $19 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 105 | $56 | $352 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 98 | $48 | $426 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 83 | $26 | $200 |
| Injection, diphenhydramine hcl, up to 50 mg | 79 | $1 | $37 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 70 | $16 | $154 |
| Injection, zoledronic acid, 1 mg | 64 | $6 | $52 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 60 | $133 | $993 |
| Infusion into a vein for hydration, 31-60 minutes | 59 | $25 | $345 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 56 | $15 | $143 |
| New patient office visit (45-59 min) | 52 | $132 | $707 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 50 | $1 | $79 |
| Administration of chemotherapy into vein using push technique | 27 | $77 | $640 |
| Injection of drug or substance into vein | 24 | $29 | $600 |
| Administration of additional new drug or substance into vein using push technique | 23 | $43 | $370 |
| New patient office visit, complex (60-74 min) | 13 | $137 | $891 |
Industry Payment Transparency
Open Payments through 2023 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2023)
Associated products mentioned in payments ›
The majority of payments (99%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Attia is a mixed practice specialist, with above-average Medicare volume (top 5% in FL), and consulting-driven industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Attia experienced with filgrastim injection (nivestym) for white blood cells?
Does Dr. Attia receive payments from pharmaceutical companies?
How do Dr. Attia's costs compare to other hematology & oncologys in Jacksonville?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology